BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II…
Ranked competitors and alternatives for this company are available inside Xcout Intel. Subscribe to open it.
Subscribe to see ブライトパス・バイオ →Already a subscriber? Sign in
Xcout Intel tracks ブライトパス・バイオ continuously — this profile deepens as new filings, funding, people and hiring data arrive.